Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systematic review and meta-analysis

Yu-Chen Huang, Yu Ning Chien, Yu Tsung Chen, Yu Chuan Li, Ting Jui Chen

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Introduction: The efficacy of intravenous immunoglobulin (IVIg) for toxic epidermal necrolysis (TEN) remains controversial, particularly for high-dose IVIg. In the present study, we conducted a SCORTE N (SCORe of Toxic Epidermal Necrosis)-based standardized mortality ratio (SMR) meta-analysis, with a focus on the efficacy of high-dose IVIg. Evidence Acquisition: A systematic review and meta-analysis of the literature published between January 01, 2000 and April 30, 2016 was conducted. Studies with >9 TEN patients receiving IVIg treatment with SCORTE N scores were included. Evidence Synthesis: Mortality rate and pooled SMR were calculated for all TEN patients and adult TEN patients receiving IVIg. Eleven studies met the inclusion criteria. The overall mortality rate of TEN patients treated with IVIg was 24.2%, with a pooled SMR of 1.00 (95% CI, 0.76-1.32; I2=0%, P=0.67). The mortality rate among adult patients treated with high-dose IVIg was 11.7%. Sub-analysis of adult patients treated with high-dose IVIg showed a pooled SMR of 0.99 (95% CI, 0.60-1.63; I2=0%, P=0.78). Conclusions: The findings of the present meta-analysis do not support the clinical benefits of IVIg for TEN, even at high-doses. Additional randomized controlled trials are required to validate this result.

Original languageEnglish
Pages (from-to)515-524
Number of pages10
JournalGiornale Italiano di Dermatologia e Venereologia
Volume151
Issue number5
Publication statusPublished - 2016

Fingerprint

Stevens-Johnson Syndrome
Intravenous Immunoglobulins
Meta-Analysis
Mortality
Therapeutics
Poisons
Necrosis
Randomized Controlled Trials

Keywords

  • Immunoglobulins, intravenous
  • Meta-analysis
  • Stevens-Johnson syndrome

ASJC Scopus subject areas

  • Medicine(all)
  • Dermatology

Cite this

Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis : A systematic review and meta-analysis. / Huang, Yu-Chen; Chien, Yu Ning; Chen, Yu Tsung; Li, Yu Chuan; Chen, Ting Jui.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 151, No. 5, 2016, p. 515-524.

Research output: Contribution to journalReview article

@article{333825b683c2431b8862fec01a628977,
title = "Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systematic review and meta-analysis",
abstract = "Introduction: The efficacy of intravenous immunoglobulin (IVIg) for toxic epidermal necrolysis (TEN) remains controversial, particularly for high-dose IVIg. In the present study, we conducted a SCORTE N (SCORe of Toxic Epidermal Necrosis)-based standardized mortality ratio (SMR) meta-analysis, with a focus on the efficacy of high-dose IVIg. Evidence Acquisition: A systematic review and meta-analysis of the literature published between January 01, 2000 and April 30, 2016 was conducted. Studies with >9 TEN patients receiving IVIg treatment with SCORTE N scores were included. Evidence Synthesis: Mortality rate and pooled SMR were calculated for all TEN patients and adult TEN patients receiving IVIg. Eleven studies met the inclusion criteria. The overall mortality rate of TEN patients treated with IVIg was 24.2{\%}, with a pooled SMR of 1.00 (95{\%} CI, 0.76-1.32; I2=0{\%}, P=0.67). The mortality rate among adult patients treated with high-dose IVIg was 11.7{\%}. Sub-analysis of adult patients treated with high-dose IVIg showed a pooled SMR of 0.99 (95{\%} CI, 0.60-1.63; I2=0{\%}, P=0.78). Conclusions: The findings of the present meta-analysis do not support the clinical benefits of IVIg for TEN, even at high-doses. Additional randomized controlled trials are required to validate this result.",
keywords = "Immunoglobulins, intravenous, Meta-analysis, Stevens-Johnson syndrome",
author = "Yu-Chen Huang and Chien, {Yu Ning} and Chen, {Yu Tsung} and Li, {Yu Chuan} and Chen, {Ting Jui}",
year = "2016",
language = "English",
volume = "151",
pages = "515--524",
journal = "Giornale Italiano di Dermatologia e Venereologia",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "5",

}

TY - JOUR

T1 - Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis

T2 - A systematic review and meta-analysis

AU - Huang, Yu-Chen

AU - Chien, Yu Ning

AU - Chen, Yu Tsung

AU - Li, Yu Chuan

AU - Chen, Ting Jui

PY - 2016

Y1 - 2016

N2 - Introduction: The efficacy of intravenous immunoglobulin (IVIg) for toxic epidermal necrolysis (TEN) remains controversial, particularly for high-dose IVIg. In the present study, we conducted a SCORTE N (SCORe of Toxic Epidermal Necrosis)-based standardized mortality ratio (SMR) meta-analysis, with a focus on the efficacy of high-dose IVIg. Evidence Acquisition: A systematic review and meta-analysis of the literature published between January 01, 2000 and April 30, 2016 was conducted. Studies with >9 TEN patients receiving IVIg treatment with SCORTE N scores were included. Evidence Synthesis: Mortality rate and pooled SMR were calculated for all TEN patients and adult TEN patients receiving IVIg. Eleven studies met the inclusion criteria. The overall mortality rate of TEN patients treated with IVIg was 24.2%, with a pooled SMR of 1.00 (95% CI, 0.76-1.32; I2=0%, P=0.67). The mortality rate among adult patients treated with high-dose IVIg was 11.7%. Sub-analysis of adult patients treated with high-dose IVIg showed a pooled SMR of 0.99 (95% CI, 0.60-1.63; I2=0%, P=0.78). Conclusions: The findings of the present meta-analysis do not support the clinical benefits of IVIg for TEN, even at high-doses. Additional randomized controlled trials are required to validate this result.

AB - Introduction: The efficacy of intravenous immunoglobulin (IVIg) for toxic epidermal necrolysis (TEN) remains controversial, particularly for high-dose IVIg. In the present study, we conducted a SCORTE N (SCORe of Toxic Epidermal Necrosis)-based standardized mortality ratio (SMR) meta-analysis, with a focus on the efficacy of high-dose IVIg. Evidence Acquisition: A systematic review and meta-analysis of the literature published between January 01, 2000 and April 30, 2016 was conducted. Studies with >9 TEN patients receiving IVIg treatment with SCORTE N scores were included. Evidence Synthesis: Mortality rate and pooled SMR were calculated for all TEN patients and adult TEN patients receiving IVIg. Eleven studies met the inclusion criteria. The overall mortality rate of TEN patients treated with IVIg was 24.2%, with a pooled SMR of 1.00 (95% CI, 0.76-1.32; I2=0%, P=0.67). The mortality rate among adult patients treated with high-dose IVIg was 11.7%. Sub-analysis of adult patients treated with high-dose IVIg showed a pooled SMR of 0.99 (95% CI, 0.60-1.63; I2=0%, P=0.78). Conclusions: The findings of the present meta-analysis do not support the clinical benefits of IVIg for TEN, even at high-doses. Additional randomized controlled trials are required to validate this result.

KW - Immunoglobulins, intravenous

KW - Meta-analysis

KW - Stevens-Johnson syndrome

UR - http://www.scopus.com/inward/record.url?scp=84991223695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991223695&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84991223695

VL - 151

SP - 515

EP - 524

JO - Giornale Italiano di Dermatologia e Venereologia

JF - Giornale Italiano di Dermatologia e Venereologia

SN - 0392-0488

IS - 5

ER -